Clinicopathology Figures and Long-term Effects of Tamoxifen Plus Radiation on Survival of Women with Invasive Ductal Carcinoma and Triple Negative Breast Cancer

Abstract

Background: Triple negative breast cancer (TNBC), characterized as estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 Her2 negative and accounting for 10-17% of all breast carcinomas, is only partially responsive to chemotherapy and suffers from a lack of clinically established targeted therapies. The aim of the current study was to evaluate the patterns of treatment and clinicopathology figures in Kurdish patients with triple-negative breast cancer, and to compare these to other reports. Materials and Methods: Between 2001 and 2014, 950 breast cancer patients were referred to our clinic. There were 74 female patients with TNBC, including 70 patients was invasive ductal carcinoma entered into our study. ER and PR positivity was defined as positive immunohistochemical staining in more than 10% of tumor cells. Immunohistochemistry assay with anti-HER2 antibodies was used to identify HER negative (0 and 1+) or positive (2+ and 3+). HER2 gene amplification was determined by fluorescent in situ hybridization (FISH). Overall survival (OS) was plotted with GraphPad Prism 5 Software using Kaplan-Meier and log-rank tests for comparison of results. Results:The mean age in the first diagnosis for 70 patients with triple TNBC and invasive ductal carcinoma was 49.6 years that range of age was 27-82 years. All of the patients were female. Of 70 patients, 23 patients had metastasis. Thirty-two patients (45.7%) were treated with tamoxifen and 39 (55.7%) with radiotherapy. Three-year, 5-year and 10-year OS rates for all patients were 82%, 72% and 64%, respectively. Conclusions: The OS in our West Iran TNBC patients is less than reported elsewhere. However, treatment with combination of tamoxifen plus radiation increases the OS and reduces the mortality rate.

The effect of ginger (Zingiber officinale) on chemotherapy‐induced nausea and vomiting in breast cancer patients: A systematic literature review of randomized controlled trials

“…The most common causes of breast cancer are genetic factors and also environmental and lifestyle risk factors such as early menarche, late menopause, low parity, giving birth at an advanced age, alcohol consumption, and obesity (Dossus & Benusiglio, ). Nowadays, cancer treatment includes surgery, chemotherapy, radiotherapy, and some other procedures; however, in the advanced stages, chemotherapy is often the only effective method of cancer treatment (Payandeh, Sadeghi, Sadeghi, & Aeinfar, ). Although, in recent years, chemotherapy agents and antiemetic drugs have had significant advancement, chemotherapy‐induced nausea and vomiting (CINV) has remained as one of the worst side effects of cancer therapy (Palatty, Haniadka, Valder, Arora, & Baliga, ).…”

The correlation between Ki-67 with other prognostic factors in breast cancer: A study in Iranian patients

“…[ 2 ] ER positivity predicts response to endocrine therapy such as antiestrogen (tamoxifen) and trastuzumab therapy (herceptin) for tumor with HER2 overexpression. [ 3 ] Ki-67 is a nuclear antigen, which exists in proliferative cells. A number of studies have shown that the immune response of Ki-67 is closely associated with the cell cycle.…”

Tamoxifen Suppresses Brain Metastasis of Estrogen Receptor-deficient Breast Cancer by Skewing Microglia Polarization and Enhancing Their Immune Functions

“…showed that tamoxifen increased the overall survival and disease-free survival rate in ER -/PR + breast cancer patients [79]. In addition, treatment with combination of tamoxifen and radiation increased the overall survival rate and reduced the mortality rate of patients with brain metastasis of triple negative tumors [80]. It is noteworthy that Phase I/II clinical trial for testing e cacy of Tamoxifen and anastrozole on TNBC is currently ongoing (NCT01194908 and NCT01234532).…”